abrdn Life Sciences Investors Q1 2025 Commentary
Source: SeekingAlpha
2025-05-31 00:20:00 ET
Summary
- The equity portion of the Fund fell (gross of fees) and underperformed its benchmark, the NASDAQ Biotechnology Index.
- During the first quarter of 2025, we made several changes to the portfolio.
- With Donald Trump securing his second term, uncertainty around election results has been replaced with policy ambiguity.
Fund performance
Read the full article on Seeking Alpha
For further details see:
abrdn Life Sciences Investors Q1 2025 Commentary
Arbutus Biopharma Corporation
NASDAQ: ABUS
ABUS Trading
-2.62% G/L:
$4.28 Last:
538,653 Volume:
$4.35 Open:
ABUS Latest News
March 03, 2026 04:15:00 pm
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
March 03, 2026 04:15:00 pm
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
November 13, 2025 07:30:00 am
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 07, 2025 08:00:00 am
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
ABUS Stock Data
$811,607,352
153,282,242
0.14%
53
N/A
Biotechnology & Life Sciences
Healthcare
US
Warminster
